Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority. Once‐daily glecaprevir/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks posttreatment (SVR12) across all major HCV genotypes (GTs). This t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hepatology
Asıl Yazarlar: Reau, Nancy, Kwo, Paul Y., Rhee, Susan, Brown, Robert S., Agarwal, Kosh, Angus, Peter, Gane, Edward, Kao, Jia‐Horng, Mantry, Parvez S., Mutimer, David, Reddy, K. Rajender, Tran, Tram T., Hu, Yiran B., Gulati, Abhishek, Krishnan, Preethi, Dumas, Emily O., Porcalla, Ariel, Shulman, Nancy S., Liu, Wei, Samanta, Suvajit, Trinh, Roger, Forns, Xavier
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220874/
https://ncbi.nlm.nih.gov/pubmed/29672891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30046
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller